Findings of a feasibility study into the potential for breath analysis to help doctors to differentiate between COVID-19 and other respiratory conditions were published in The Lancet on 24 October 2020. The Imspex Group’s BreathSpec® instrument showed clusters of breath compounds reflecting the effects of COVID-19’s multi-system nature. Similar clusters were found independently across research groups.
The Imspex Group is proud to have coordinated and driven the project. We are excited to be taking the results further as we validate and scale them into a cost-effective and accessible point-of-care detection tool tool that can be used for rapid and non-invasive sampling in large-scale detection programmes.